Schizophreniform Disorders
43
2
7
26
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
4.7%
2 terminated out of 43 trials
92.9%
+6.4% vs benchmark
28%
12 trials in Phase 3/4
38%
10 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (43)
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
Shared Decision Making for Antipsychotic Medications
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
Early Psychosis Intervention - Spreading Evidence-based Treatment
REWRITALIZE Your Recovery - Evaluation of a Creative Writing Group Intervention
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Academic-Community EPINET (AC-EPINET)
Remote State Representation in Early Psychosis
Horyzons: Implementation and Integration in Clinical Practice
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
EPI-MINN: Targeting Cognition and Motivation - National
Peripheral Immune System in Individuals With Schizophrenia
iTBS to Enhance Social Cognition in People With Psychosis
Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
Minnesota Community-Based Cognitive Training in Early Psychosis
Horyzons: Implementation in Clinical Practice